By Nelson Vergel Powerusa.org Dr Joe Eron presented new dosing and efficacy phase 2b data on the new GSK integrase inhibitor dolutegravir (DTG, S/GSK1349572) using 50 mg twice a day in patients whose HIV virus has developed resistance to raltegravir (Isentress). Prior data presented in Vienna from a cohort (cohort 1) of patients who took …
Dolutegravir, Trii and new abacavir data- How it all ties together Read More »
From https://www.thebody.com/content/art60472.html?ts=pf By Nelson Vergel February 14, 2011 “Nelson, what am I going to do?” This sentence is part of a conversation that I seem to be having everywhere I go with my seminars — one that manifests from a communal concern that many of us are sharing as we age as HIV long-term survivors. …
Zinc Fingers and Gene Therapies for HIV: Mimicking the Cured Berlin Patient? By Nelson Vergel March 2, 2011 Jay Lalezari, M.D., from the University of California-San Francisco presented first-of-its-kind study data on the use of zinc finger nucleases (ZFNs) to artificially disrupt the CCR5 receptor on the surface of CD4 cells, which HIV uses to infect its …
Zinc Fingers and Gene Therapies for HIV: Mimicking the Cured Berlin Patient? Read More »
This will make it possible for GSK-ViiV to market their new Trii formulation of the new integrase inhibitor GSK572 (generic name: dolutegravir) plus Epzicom (abacavir plus epivir) as a once a day pill for naive patients It contradicts all the previous studies that said that abacavir (Ziagen) causes increased cardiovascular risks. https://www.aidsmap.com/page/1682771/ GSK is currently …
